Nyra Medical, Inc., a medical device business developing a revolutionary transcatheter mitral valve replacement technique, announced the completion of a USD 20 million Series A fundraising round. Vensana Capital and an extensive global medical device company led the round, with Epidarex Capital, Broadview Ventures and the Georgia Research Alliance Venture Fund also participating. The funds raised will support Nyra’s technology through early feasibility clinical trials.
Nyra is developing a transcatheter device (CARLEN) that changes the native mitral valve leaflets using a unique implant to rectify inadequacies that might otherwise result in mitral regurgitation while retaining physiological valve shape.
“We now know that correcting mitral regurgitation in heart failure patients can reduce mortality and hospitalization rates, with earlier intervention yielding the best results,” says Murali Padala, Ph.D., inventor of CARLEN, Director of Emory University’s Carlyle Fraser Cardiothoracic Research Laboratories, and founder of Nyra Medical.
Eric L. Sarin, MD, co-founder of the firm:
“A transcatheter therapy that may enhance effectiveness and safety while remaining simple is the ‘holy grail’ of structural heart disease treatment. The Nyra team recognized this fact and designed an elegant device that meets numerous current requirements in treating valvular heart disease.”
Amrinder Singh, Principal at Vensana Capital, stated:
“The transcatheter mitral repair market is still in its early stages, with plenty of possibilities for expansion. Nyra’s technology offers an elegant treatment option and is a logical next step in the progression of catheter-based advances for treating mitral regurgitation. Our team and clinical advisors are very excited about CARLEN’s potential as a treatment for mitral valve disease.
With this fresh round of funding, Nyra has appointed Lisa Wipperman Heine as an independent director to its board of directors. Lisa is a seasoned medical technology professional with over 25 years of experience in operational, management, and board positions. She was most recently the CEO of preCARDIA. Before that, she was the COO of Mitralign and held several leadership positions at Covidien, including Global Vice President of Medical Affairs for Vascular Therapies.
More about the company:
With the motto ” Simplifying transcatheter repair of heart valves…one valve at a time,” Nyra Medical is a medical device company that develops the CARLEN technology, the transcatheter technology for the treatment of mitral regurgitation. CARLEN help preserves the natural valve form while restoring function, eliminates the potential of stenosis, and preserves future transcatheter and surgical therapy options.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
